Cancer patients may experience delayed skin effects of anti-PD-1 therapy
Cancer patients receiving anti-PD-1 therapies who develop lesions, eczema, psoriasis, or other forms of auto-immune diseases affecting the skin may experience those adverse reactions on a delay—sometimes even after treatment has concluded, according to new research from the Perelman School of Medicine published in JAMA Dermatology.
FULL STORY AT Penn Medicine News →